Hyperadrenergic POTS: The High-Norepinephrine Subtype Explained

Hyperadrenergic POTS is the most physiologically distinct subtype of postural orthostatic tachycardia syndrome, and it is also the most commonly misdiagnosed. While all POTS subtypes involve an abnormal heart rate increase on standing, hyperadrenergic POTS is defined by a surge in norepinephrine — the primary sympathetic neurotransmitter — that produces a constellation of symptoms that can mimic anxiety disorders, panic attacks, and even pheochromocytoma.

Defining Hyperadrenergic POTS

Hyperadrenergic POTS is defined by:

1. Meeting standard POTS criteria (heart rate increase ≥30 bpm within 10 minutes of standing, or ≥40 bpm in patients under 19)
2. Plasma norepinephrine ≥600 pg/mL when upright (normal standing norepinephrine is 200–400 pg/mL)
3. Often: blood pressure that rises (rather than falls) on standing
4. Often: a paradoxical worsening of symptoms with beta-blockers at standard doses

Hyperadrenergic POTS accounts for approximately 10–15% of POTS cases, though it may be underdiagnosed because plasma norepinephrine testing is not routinely performed.

What Causes the Norepinephrine Surge?

The norepinephrine surge in hyperadrenergic POTS can arise from several mechanisms:

Impaired norepinephrine reuptake. The norepinephrine transporter (NET) is responsible for recycling norepinephrine back into sympathetic nerve terminals after release. In some hyperadrenergic POTS patients, NET function is impaired — either due to genetic variants in the SLC6A2 gene (which encodes NET) or autoimmune damage to sympathetic nerve terminals. This allows norepinephrine to accumulate in the synapse and spill over into the bloodstream.

Sympathetic nervous system hyperactivation. In some patients, the sympathetic nervous system is simply overactive — firing more norepinephrine in response to orthostatic stress than is physiologically appropriate. This can be driven by central sensitization, mast cell activation (histamine directly stimulates sympathetic nerve firing), or anxiety-autonomic feedback loops.

Mast cell-mediated norepinephrine release. Mast cells in the adrenal medulla and sympathetic ganglia can trigger norepinephrine release when activated. This is why hyperadrenergic POTS and MCAS so frequently co-occur — mast cell degranulation triggers norepinephrine surges, which worsen POTS symptoms, which trigger more mast cell activation.

Symptoms of Hyperadrenergic POTS

The symptom profile of hyperadrenergic POTS is distinct from other subtypes:

The anxiety-like symptoms are particularly important to recognize. Hyperadrenergic POTS patients are frequently diagnosed with panic disorder or generalized anxiety disorder before the correct diagnosis is made. The key distinction is that the symptoms are triggered by standing and relieved by lying down — a pattern that is not typical of primary anxiety disorders.

Diagnosis

Plasma norepinephrine testing is the definitive test. Blood is drawn supine after 20–30 minutes of rest, then again after 10 minutes of standing. A standing norepinephrine ≥600 pg/mL confirms the hyperadrenergic subtype.

Tilt table test in hyperadrenergic POTS typically shows a rising blood pressure on tilt (rather than the falling blood pressure seen in vasovagal syncope) alongside tachycardia.

24-hour urine catecholamines can help rule out pheochromocytoma, which can mimic hyperadrenergic POTS. Pheo typically produces much higher catecholamine levels and paroxysmal hypertensive crises.

Treatment

Treatment of hyperadrenergic POTS differs significantly from other subtypes:

Clonidine (an alpha-2 agonist that reduces sympathetic outflow) is often the most effective first-line medication. It directly reduces norepinephrine release and can dramatically improve symptoms. Starting dose is typically 0.05–0.1 mg twice daily.

Low-dose beta-blockers with caution. Standard beta-blocker doses (propranolol 20–40 mg) can worsen symptoms in hyperadrenergic POTS by blocking beta-2 receptors (causing vasoconstriction) while leaving alpha-1 receptors unopposed (causing hypertension). Very low doses (propranolol 5–10 mg) are sometimes tolerated and can reduce heart rate without worsening blood pressure.

Methyldopa (a central alpha-2 agonist) is an alternative to clonidine with a longer duration of action.

MCAS treatment. If MCAS is driving the norepinephrine surges, treating MCAS with H1/H2 antihistamines and mast cell stabilizers can dramatically reduce hyperadrenergic episodes.

Avoid: High-dose beta-blockers, fludrocortisone (which raises blood pressure further), and vasoconstrictors (midodrine) — all of which can worsen hypertensive episodes in hyperadrenergic POTS.